5279-23-2

Basic information

• Product Name: 1-(4-chlorophenyl)sulfonyl-4-(2-methoxyphenyl)piperazine
• Synonyms: 1-(4-chlorophenyl)sulfonyl-4-(2-methoxyphenyl)piperazine
• CAS NO: 5279-23-2
• Molecular Formula: C₁₃H₂₁NO₂
• Molecular Weight: 367
• Mol File: 5279-23-2.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 526.6°Cat760mmHg
• Flash Point: 272.3°C
• Appearance: /
• Density: 1.329g/cm³
• Vapor Pressure: 3.52E-11mmHg at 25°C
• Refractive Index: 1.61
• CAS DataBase Reference: 1-(4-chlorophenyl)sulfonyl-4-(2-methoxyphenyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-chlorophenyl)sulfonyl-4-(2-methoxyphenyl)piperazine(5279-23-2)
• EPA Substance Registry System: 1-(4-chlorophenyl)sulfonyl-4-(2-methoxyphenyl)piperazine(5279-23-2)

Safety Data

• Hazardous Substances Data: 5279-23-2(Hazardous Substances Data)

Usage

Description

1-(4-chlorophenyl)sulfonyl-4-(2-methoxyphenyl)piperazine, also known as CSP, is a piperazine derivative characterized by a sulfonyl group attached to a piperazine ring, with a 4-chlorophenyl group and a 2-methoxyphenyl group at different positions of the ring. It is known for its potential pharmacological activities, including antipsychotic, anxiolytic, anti-inflammatory, and neuroprotective properties.

Uses

Used in Pharmaceutical Industry:
1-(4-chlorophenyl)sulfonyl-4-(2-methoxyphenyl)piperazine is used as a potential therapeutic agent for psychiatric conditions such as schizophrenia and bipolar disorder, due to its antipsychotic and anxiolytic properties.
Used in Neurological Applications:
CSP is used as a potential neuroprotective agent, which may help in the treatment and prevention of neurodegenerative diseases and conditions.
Used in Anti-inflammatory Applications:
1-(4-chlorophenyl)sulfonyl-4-(2-methoxyphenyl)piperazine is used as an anti-inflammatory agent, which may be beneficial in treating various inflammatory conditions and diseases.
Used in Research and Development:
CSP is used as a compound of interest in preclinical studies, where its unique chemical structure and diverse biological activities make it a promising candidate for further research and potential therapeutic development.

InChI:InChI=1/C17H19ClN2O3S/c1-23-17-5-3-2-4-16(17)19-10-12-20(13-11-19)24(21,22)15-8-6-14(18)7-9-15/h2-9H,10-13H2,1H3

Upstream product

• 100-46-9 benzylamine 
• 793-19-1 bis(2-methoxycarbonylethyl)benzylamine 
• 627-30-5 1-chloro-3-hydroxypropane 
• 14002-33-6 bis-(3-hydroxypropyl)amine 
• 100-39-0 benzyl bromide 
• 6938-07-4 N,N-bis(2-ethoxycarbonylethyl)benzylamine 

Downstream Products

• 34753-62-3 N-Benzylbis(3-chloropropyl)amine 
• 14002-33-6 bis-(3-hydroxypropyl)amine 
• 180966-22-7 N-tert-butoxycarbonyl-bis(3-chloropropyl)amine 
• 180965-94-0 5-Benzyl-1,9-dithia-5,13-diazacyclohexadecane 
• 180966-02-3 5-benzyl-1,9-dithia-13-chloroacetyl-5,13-diazacyclohexadecane 
• 180965-92-8 5-benzyl-13-tert-butoxycarbonyl-1,9-dithia-5,13-diazacyclohexadecane 
• 180966-21-6 1,3,5-tris[(1,9-dithia-5,13-diazacyclohexadec-5-yl)methyl]benzene 
• 180966-20-5 [3,5-Bis-(1,9-dithia-5,13-diaza-cyclohexadecane-5-carbonyl)-phenyl]-(1,9-dithia-5,13-diaza-cyclohexadec-5-yl)-methanone 
• 180966-14-7 1,3,5-tris[2-(1,9-dithia-5,13-diazacyclohexadec-5-yl)ethoxy]benzene 
• 180966-12-5 2-{3,5-Bis-[2-(1,9-dithia-5,13-diaza-cyclohexadec-5-yl)-2-oxo-ethoxy]-phenoxy}-1-(1,9-dithia-5,13-diaza-cyclohexadec-5-yl)-ethanone 
• 180966-16-9 (13-Benzyl-1,9-dithia-5,13-diaza-cyclohexadec-5-yl)-[3,5-bis-(13-benzyl-1,9-dithia-5,13-diaza-cyclohexadecane-5-carbonyl)-phenyl]-methanone 
• 180966-19-2 1,3,5-tris[(13-tert-butoxycarbonyl-1,9-dithia-5,13-diazacyclohexadec-5-yl)carbonyl]benzene 
• 180966-06-7 1-(13-Benzyl-1,9-dithia-5,13-diaza-cyclohexadec-5-yl)-2-{3,5-bis-[2-(13-benzyl-1,9-dithia-5,13-diaza-cyclohexadec-5-yl)-2-oxo-ethoxy]-phenoxy}-ethanone 
• 180966-10-3 1,3,5-tris[(13-tert-butoxycarbonyl-1,9-dithia-5,13-diazacyclohexadec-5-yl)carbonylmethoxy]benzene 

Relevant articles and documents

TRIAZACYCLODODECANSULFONAMIDE ("TCD")-BASED PROTEIN SECRETION INHIBITORS

Provided herein are triazacyclododecansulfonamide ("TCD")-based protein secretion inhibitors, such as inhibitors of Sec61, methods for their preparation, related pharmaceutical compositions, and methods for using the same. For example, provided herein are compounds of Formula (I) and pharmaceutically acceptable salts and compositions including the same. The compounds disclosed herein may be used, for example, in the treatment of diseases including inflammation and/or cancer.

Synthesis and structural characterization of 20-membered macrocyclic rings bearing: Trans -chelating bis(N-heterocyclic carbene) ligands and the catalytic activity of their palladium(ii) complexes

Macrocycles consisting of a 20-membered ring containing two imidazolium salt functionalities and of the formula [PhCH2N(CH2CH2CH2)Im(CH2CH2CH2)2][Br]2 (Im = imidazole = 3a, benzimidazole = 3b) were synthesized in 70-75% yields. These salts serve as precursors to macrocycles containing two N-heterocyclic carbene (NHC) moieties. Reaction of the macrocyclic salts 3a and 3b with silver oxide afforded macrocyclic-bis(NHC)silver(i) complexes 4a and 4b. Single-crystal X-ray diffraction studies of macrocyclic-bis(NHC)silver(i) complex 4a revealed a tetranuclear silver core with a short Ag-Ag distance (2.9328 ?). Complexes 4a and 4b serve as carbene transfer reagents to Pd. The treatment of macrocyclic-bis(NHC)silver(i) complexes 4a and 4b with one equivalent of PdCl2(MeCN)2 in methylene chloride afforded square-planar trans-macrocyclic-bis(NHC)Pd(ii)X2 complexes 5a and 5b. Preliminary screening of these palladium complexes showed they are competent precatalysts for Heck and Suzuki coupling reactions.

New bidentate trans-chelating N-heterocyclic carbene ligands for palladium

A family of imidazolium salts of the type [BnN(CH2CH 2CH2RIm)2]A·2[Cl] (Bn = CH2Ph; RIm = 1-methylimidazole (1a), 1-tert-butylimidazole (1b), 1-benzylimidazole (1c), 1-methylbenzimidazole (1d)), which contain a tertiary amine linking two imidazolium groups, has been synthesized. These imidazolium salts can be deprotonated with Ag2O to generate the Ag carbene complexes [{BnN(CH2CH2CH2 RIm)2}Ag].[AgCl2] (RIm = 1-methylimidazole (2a), 1-tert-butylimidazole (2b), 1-benzylimidazole (2c), 1-methylbenzimidazole (2d)). In the solid state 2d exists as an unusual tetramer, which consists of an [Ag2Cl4]2- core bridging two Ag(NHC) cations. Subsequent reaction of the Ag complexes with PdCl2(MeCN)2 generates Pd species of the type {BnN(CH 2CH2CH2RIm)2}PdCl 2 (RIm = 1-methylimidazole (3a), 1-tert-butylimidazole (3b), 1-benzylimidazole (3c), 1-methylbenzimidazole (3d)), which is a rare example of a family of Pd complexes that contain a bidentate trans-chelating N-heterocyclic carbene ligand. Compounds 3a and 3c were crystallographically characterized by X-ray crystallography and contain unusual 12-membered metallacycles. DFT calculations suggest that the preference for trans binding of the ligand is related to conformational effects of the linker. Compound 3b reacts with excess MeI to form {BnN(CH2CH2CH 2tBuIm)2}PdI2 (5b), a reaction in which we believe a Pd(IV) intermediate is generated. Compound 5b was crystallographically characterized. Compounds 3a-d are all active catalysts for the Heck reaction, and 3a can also catalyze the Suzuki reaction.